Volume | 6,451 |
|
|||||
News | - | ||||||
Day High | 1.87 | Low High |
|||||
Day Low | 1.81 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.81 | 1.81 | 1.87 | 1.81 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
60 | 6,451 | $ 1.84 | $ 11,866 | - | 1.60 - 37.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:50:39 | 56 | $ 1.86 | USD |
eFFECTOR Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.51M | 3.00M | - | 0 | -35.81M | -11.95 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
eFFECTOR Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 2.00 | 1.60 | 1.81 | 162,485 | 0.06 | 3.33% |
1 Month | 14.37 | 16.882 | 1.60 | 3.21 | 875,044 | -12.51 | -87.06% |
3 Months | 11.03 | 17.75 | 1.60 | 6.01 | 400,312 | -9.17 | -83.14% |
6 Months | 13.725 | 17.90 | 1.60 | 11.65 | 1,228,785 | -11.87 | -86.45% |
1 Year | 9.93 | 37.00 | 1.60 | 16.57 | 1,267,552 | -8.07 | -81.27% |
3 Years | 475.00 | 1,010.50 | 1.60 | 117.01 | 792,306 | -473.14 | -99.61% |
5 Years | 475.00 | 1,010.50 | 1.60 | 117.01 | 792,306 | -473.14 | -99.61% |
eFFECTOR Therapeutics Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |